Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL® (posaconazole) Receives FDA

  Merck’s New Drug Application for an Investigational Intravenous (IV)
  Formulation of NOXAFIL® (posaconazole) Receives FDA Priority Review

  Marketing Authorization Application also Filed with the European Medicines
                                    Agency

Business Wire

WHITEHOUSE STATION, N.J. -- November 18, 2013

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today
announced that its New Drug Application for an investigational intravenous
(IV) solution formulation of the company's antifungal agent, NOXAFIL^®
(posaconazole), has been accepted for priority review by the U.S. Food and
Drug Administration (FDA).

Priority review designation is assigned to applications for drugs that, if
approved, would provide significant improvements in the safety or
effectiveness of the treatment, diagnosis or prevention of serious conditions.

The company also has filed a marketing authorization application for NOXAFIL
IV solution with the European Medicines Agency (EMA) and plans to seek
regulatory approval for the IV formulation in other countries around the
world.

Merck currently markets NOXAFIL Oral Suspension in the U.S. for prophylaxis of
invasive Aspergillus and Candida infections in patients 13 years of age and
older who are at high risk of developing these infections due to being
severely immunocompromised, such as patients who have received hematopoietic
stem cell transplants and have graft-versus-host disease, or patients with
cancers of the blood who are experiencing prolonged low white blood cell
counts (neutropenia) as a result of chemotherapy.

In April, Merck announced that it had filed new drug applications for an
investigational, tablet formulation of NOXAFIL with both the FDA and EMA.
These applications are currently under review.

Selected safety information about NOXAFIL Oral Suspension

NOXAFIL is contraindicated in persons with known hypersensitivity to
posaconazole, any component of NOXAFIL, or other azole antifungal agents.

NOXAFIL (posaconazole) is contraindicated with sirolimus. Concomitant
administration of NOXAFIL with sirolimus increases the sirolimus blood
concentrations by approximately 9-fold and can result in sirolimus toxicity.

NOXAFIL is contraindicated with CYP3A4 substrates that prolong the QT
interval. Concomitant administration of NOXAFIL with the CYP3A4 substrates
pimozide and quinidine may result in increased plasma concentrations of these
drugs, leading to QTc prolongation and rare occurrences of torsades de
pointes.

NOXAFIL is contraindicated with HMG-CoA reductase inhibitors that are
primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and
simvastatin) as increased plasma concentration of these drugs can lead to
rhabdomyolysis.

NOXAFIL is contraindicated with ergot alkaloids. NOXAFIL may increase the
plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine)
which may lead to ergotism.

Concomitant administration of NOXAFIL with cyclosporine or tacrolimus
increases the whole blood trough concentrations of these calcineurin
inhibitors. Nephrotoxicity and leukoencephalopathy (including isolated deaths)
have been reported in clinical efficacy studies in patients with elevated
cyclosporine concentrations. Frequent monitoring of cyclosporine or tacrolimus
whole blood trough concentrations should be performed during and at
discontinuation of NOXAFIL treatment and the tacrolimus or cyclosporine dose
adjusted accordingly.

Some azoles, including NOXAFIL, have been associated with prolongation of the
QT interval on the electrocardiogram. In addition, rare cases of torsades de
pointes have been reported in patients taking NOXAFIL. NOXAFIL should be
administered with caution to patients with potentially proarrhythmic
conditions. Rigorous attempts to correct potassium, magnesium, and calcium
should be made in these patients before starting NOXAFIL.

Hepatic reactions (e.g., mild to moderate elevations in ALT, AST, alkaline
phosphatase, total bilirubin, and/or clinical hepatitis) have been reported in
clinical trials. The elevations in liver function tests were generally
reversible on discontinuation of therapy, and in some instances these tests
normalized without drug interruption and rarely required drug discontinuation.
Isolated cases of more severe hepatic reactions including cholestasis or
hepatic failure including deaths have been reported in patients with serious
underlying medical conditions (e.g., hematologic malignancy) during treatment
with NOXAFIL. Liver function tests should be evaluated at the start of and
during the course of therapy. Discontinuation of NOXAFIL must be considered if
clinical signs and symptoms consistent with liver disease develop that may be
attributable to NOXAFIL.

Concomitant administration of NOXAFIL (posaconazole) with midazolam increases
the midazolam plasma concentrations by approximately 5-fold. Increased plasma
midazolam concentrations could potentiate and prolong hypnotic and sedative
effects. Patients must be monitored closely for adverse effects associated
with high plasma concentrations of midazolam and benzodiazepine receptor
antagonists must be available to reverse these effects.

NOXAFIL has been shown to interact with several medications, including drugs
that suppress the immune system, and these reactions may be serious. NOXAFIL
is also a strong inhibitor of CYP3A4. Therefore, plasma concentrations of
drugs predominantly metabolized by CYP3A4 may be increased by NOXAFIL. The
product label should be consulted when other drugs are prescribed with
NOXAFIL.

Co-administration of NOXAFIL with rifabutin, phenytoin, efavirenz, cimetidine
and esomeprazole should be avoided unless the benefit outweighs the risk.
Monitoring for toxicity and adverse events is recommended when tacrolimus,
cyclosporine, ritonavir, atazanavir, vinca alkaloids, and calcium channel
blockers and rifabutin are co-administered with NOXAFIL. Dosage adjustments
should also be considered when tacrolimus, cyclosporine, vinca alkaloids,
calcium channel blockers, and phenytoin are administered with NOXAFIL. Monitor
plasma concentrations when co-administering digoxin, phenytoin, tacrolimus and
cyclosporine with NOXAFIL. Monitor for breakthrough fungal infections when
co-administering metoclopramide, fosamprenavir, rifabutin, phenytoin,
cimetidine and esomeprazole with NOXAFIL.

The safety and effectiveness of NOXAFIL in patients below the age of 13 years
old have not been established.

The most common adverse reactions (>30%) in the prophylaxis clinical studies
were fever, diarrhea, and nausea.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside of the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline products
that the products will receive the necessary regulatory approvals or that they
will prove to be commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck patents
and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2012
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

NOXAFIL^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Whitehouse Station, N.J., USA.

                                    # # #

Please see Prescribing Information for NOXAFIL (posaconazole) at
http://www.spfiles.com/pinoxafil.pdf and Patient Information for NOXAFIL at
http://www.spfiles.com/ppinoxafil.pdf.

Contact:

Merck
Media Contacts:
Pam Eisele, 908-423-5042
or
Robert Consalvo, 908-423-6595
or
Investor Contacts:
Carol Ferguson, 908-423-4465
or
Justin Holko, 908-423-5088